Cargando…

COVID‐19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience

Substantial changes in the management of cancer patients have been required worldwide in response to the COVID‐19 pandemic. Beyond the due details on the primitive cancer site and setting at diagnosis, these latter adaptions are most commonly exemplified by a significant reduction in the screening o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barba, Maddalena, Krasniqi, Eriseld, Pizzuti, Laura, Mazzotta, Marco, Marinelli, Daniele, Giuliano, Greta, Di Liso, Francesca Sofia, Cappuzzo, Federico, Landi, Lorenza, Tomao, Silverio, Ciliberto, Gennaro, Vici, Patrizia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251317/ https://www.ncbi.nlm.nih.gov/pubmed/33677841 http://dx.doi.org/10.1111/tbj.14204

Ejemplares similares

Burnout of health care providers during the COVID-19 pandemic: Focus on Medical Oncologists
por: Vici, Patrizia, et al.
Publicado: (2021)

Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer
por: Mazzotta, Marco, et al.
Publicado: (2019)

Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors
por: Vici, Patrizia, et al.
Publicado: (2020)

Cancer patients and coronavirus disease 2019: evidence in context
por: Barba, Maddalena, et al.
Publicado: (2020)

Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives
por: Krasniqi, Eriseld, et al.
Publicado: (2021)

Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials
por: Marinelli, Daniele, et al.
Publicado: (2020)

Highly durable response to capecitabine in patient with metastatic estrogen receptor positive breast cancer: A case report
por: Barchiesi, Giacomo, et al.
Publicado: (2019)

Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?
por: Mazzotta, Marco, et al.
Publicado: (2021)

Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane
por: Krasniqi, Eriseld, et al.
Publicado: (2020)

Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration
por: Krasniqi, Eriseld, et al.
Publicado: (2022)

Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios
por: Pizzuti, Laura, et al.
Publicado: (2019)

Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2020)

Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting
por: Grassadonia, Antonino, et al.
Publicado: (2021)

Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial
por: Pizzuti, Laura, et al.
Publicado: (2020)

The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study
por: Krasniqi, Eriseld, et al.
Publicado: (2022)

MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study
por: Krasniqi, E., et al.
Publicado: (2021)

Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting
por: Di Benedetto, Anna, et al.
Publicado: (2019)

Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial
por: Krasniqi, Eriseld, et al.
Publicado: (2021)

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
por: Krasniqi, E., et al.
Publicado: (2019)

Emerging Biological Treatments for Uterine Cervical Carcinoma
por: Vici, Patrizia, et al.
Publicado: (2014)

Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting
por: Mandoj, Chiara, et al.
Publicado: (2018)

DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study
por: Bon, Giulia, et al.
Publicado: (2023)

Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes
por: Mazzotta, Marco, et al.
Publicado: (2020)

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients
por: Vici, Patrizia, et al.
Publicado: (2013)

Multicohort and cross‐platform validation of a prognostic Wnt signature in colorectal cancer
por: Goeman, Frauke, et al.
Publicado: (2020)

Immunologic treatments for precancerous lesions and uterine cervical cancer
por: Vici, Patrizia, et al.
Publicado: (2014)

Breast cancer surgery during the Covid-19 pandemic: a monocentre experience from the Regina Elena National Cancer Institute of Rome
por: Pelle, Fabio, et al.
Publicado: (2020)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2021)

Niraparib in ovarian cancer: results to date and clinical potential
por: Caruso, Davide, et al.
Publicado: (2017)

CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives
por: Roberto, Michela, et al.
Publicado: (2021)

Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach
por: Tomao, Federica, et al.
Publicado: (2013)

Pretreated EGFR(del19)/BRAF(V600E) Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report
por: Orciuolo, Corrado, et al.
Publicado: (2023)

Prognostic value of [18F]-FDG PET/CT in patients with meta-static breast cancer treated with cyclin-dependent inhibitors
por: Annovazzi, Alessio, et al.
Publicado: (2023)

Triple-negative breast cancer: new perspectives for targeted therapies
por: Tomao, Federica, et al.
Publicado: (2015)

How selecting best upfront therapy for metastatic disease?—Focus on ROS1-rearranged disease
por: Landi, Lorenza, et al.
Publicado: (2020)

The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world
por: Giacomini, Patrizio, et al.
Publicado: (2023)

The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature
por: Botticelli, Andrea, et al.
Publicado: (2022)

Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
por: Grassadonia, Antonino, et al.
Publicado: (2018)

Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer
por: De Nicola, Francesca, et al.
Publicado: (2018)

Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer
por: Pallocca, Matteo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4v8a3dru2o8sofjon794hrsrdu